Steven Skolsky joins Quintiles

To head the clinical development leadership team

Quintiles, a US-headquartered biopharmaceutical firm, has appointed Steven Skolsky as global head of its Clinical & Data Operations (CDO) unit, the core of the company’s Clinical Development division that monitors the clinical conduct at research sites and collects and manages data from patients in clinical trials conducted around the world.

A 30-year veteran of the biopharmaceutical industry, Skolsky will lead the CDO unit, which unites Clinical Data Management and Clinical Operations under one umbrella, and employees 5,000 people.

Skolsky previously served as vice chairman of the board and is a current board director for Basilea Pharmaceutica, a Basel, Switzerland-based pharmaceutical company. He is also on the board of directors of Adherex Technologies, a clinical stage oncology company based in Raleigh, NC. Most recently, he was principal at Expis Partners, a strategic life science consultancy.

In a separate announcement, Quintiles has opened its new European headquarters in Reading, UK, bringing together more than 500 staff who were previously in three separate offices.

Quintiles employs more than 2,000 people in the UK and more than 9,000 across Europe, Middle East and Africa.

You may also like

Manufacturing

Quintiles to acquire Novella Clinical

To boost its small biopharma, oncology and medical device capabilities
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Mega deals and job cuts

Mergers and acquisitions, job cuts as companies streamlined their operations and cut costs, and investments in new plants were the main features of the pharmaceutical industry in 2012
Research & Development

Quintiles acquires Expression Analysis

To boost its genomics services and advance personalised medicine
Regulatory

Quintiles invests a further US$14m in China

Will also expand lab testing capabilities with SCRC
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Picking up a good deal

This month Asia correspondent A Nair looks at why the emerging economies provide so many tempting takeover targets for Big Pharma
Research & Development

Quintiles becomes major shareholder in Oxford Cancer Biomarkers

Firm will develop cancer biomarkers and provide oncology consultancy
Regulatory

Quintiles launches Kun Tuo CRO in China

Will develop customised solutions to assist registration of new medicines in China
Subscribe now